Showing 4341-4350 of 9719 results for "".
- Senté to Introduce Intensive Bio Complete Creamhttps://practicaldermatology.com/news/sent-to-introduce-intensive-bio-complete-cream/2459927/Senté is expanding their family of skincare products with the upcoming launch of Intensive Bio Complete Cream. Slated to be available on Feb. 11, 2019, the new nighttime cream is an “advanced retinol,” explains Virginia L. Vega, Ph.D., Senté ’s Vice
- Cosmetic Surgery Forum Kicks Off in Las Vegashttps://practicaldermatology.com/news/cosmetic-surgery-forum-kicks-off-in-las-vegas/2457493/With new and returning faculty, controversial and timely topics, and an all new venue, Cosmetic Surgery Forum (CSF) kicks off its 10th year at the chic Cosmopolitan Hotel. The meeting features 50 sessions and a robust exhibit floor. This year’s Cosmetic Surgery Foru
- CeraVe Launches Hyaluronic Acid Serum, Line of Products for Diabetic Skinhttps://practicaldermatology.com/news/cerave-launches-hyaluronic-acid-serum-line-of-products-for-diabetic-skin/2457497/L'Oréal’s CeraVe is rolling out a Hydrating Hyaluronic Acid Serum and a Diabetics' Dry Skin Relief line, which includes a Moisturizing Cream, Hand and Foot Cream and a Cleansing Wash. Hitting shelves in late 2018, the Diabetics'
- Sonoma Pharmaceuticals Launches New Ceramax Skin Barrier Lotionhttps://practicaldermatology.com/news/sonoma-pharmaceuticals-launches-new-ceramax-skin-barrier-lotion/2457504/Sonoma Pharmaceuticals, Inc. has launched a new Ceramax™ Skin Barrier Lotion that complements Sonoma’s current Ceramax Skin Barrier Cream. Both Ceramax products contain skin-enriching technology that helps manage dry itchy skin,
- Industry Vet Todd Zavodnick Joins Dermavent Sciences as CEOhttps://practicaldermatology.com/news/industry-vet-todd-zavodnick-joins-dermavent-sciences-as-ceo/2457506/Todd Zavodnick is the new Chief Executive Officer of Dermavant Sciences, a dermatology-focused subsidiary of Roivant Sciences. "It is an honor to join Dermavant at such an exciting time in the company's growth," says Mr. Zavodnick in a news release. "Medical dermatology
- Novan: Top Line Phase 2 Data Positive for SB206 Gel for Molluscumhttps://practicaldermatology.com/news/novan-top-line-phase-2-data-positive-for-sb206-gel-for-molluscum/2457507/Top line results from Novan’s Phase 2 clinical trial to evaluate topical nitric oxide product candidate SB206 for the treatment of molluscum contagiosum are promising. Data for three full cohorts of four show that SB206 gel demonstrated a clear treatment effect on the complete clearance of
- The American Dermatological Association Is On Board with American Cancer Society's HPV Vaccine Policyhttps://practicaldermatology.com/news/the-american-dermatological-association-is-on-board-with-american-cancer-societys-hpv-vaccine-policy/2457513/The American Dermatological Association is co-sponsoring the American Cancer Society’s public policy of vaccination against Human Papillomavirus infections [HPV] beginning at age 11 or 12 for girls and boys. HPV is associated with protean medical illne
- Pennsylvania Passes SUNucate, Allowing Sunscreen Use and Protective Clothing at Schoolhttps://practicaldermatology.com/news/pennsylvania-passes-sunucate-allowing-sunscreen-use-and-protective-clothing-at-school/2457529/Pennsylvania became the 17th state to allow children to possess and apply sunscreen at school. Governor Tom Wolf approved HB 1228, a piece of legislation based on American Society for Dermatologic Surgery Association’s (ASDA) model bill known as SUNucate<
- Ilumya Now Available for Moderate-to-Severe Plaque Psoriasishttps://practicaldermatology.com/news/ilumya-now-available-for-moderate-to-severe-plaque-psoriasis/2457534/Ilumya™ (tildrakizumab-asmn) 100mg/mL from Sun Pharmaceutical Industries Ltd. is now available in the United States. Ilumya is an injectable interleukin-23 (IL-23) inhibitor approved by the FDA for the treatment of moderate-to-severe plaque psoriasis in adults who are candidates for s
- FDA Green Lights First Spray-on-Skin Product for Burnshttps://practicaldermatology.com/news/fda-green-lights-first-spray-on-skin-product-for-burns/2457598/The US Food and Drug Administration granted premarket approval to Avita Medical’s Recell, a spray-on-skin that treats second- and third-degree burns in patients aged older than 18 years. The U.S. market launch for the Recell Autologous Cell Harvesting Device (RECELL® System) is